Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 02, 2026 02:00 ET | Source: Greywolf Therapeutics

Greywolf Therapeutics reports durable clinical responses with first-in-class oral ERAP1 inhibitor GRWD5769 across six solid tumor types

First-in-class oral ERAP1 inhibitor shows 13–36% ORR across 6 solid tumor types in anti-PD-1 resistant patients
April 16, 2026 02:00 ET | Source: Greywolf Therapeutics

Greywolf Therapeutics appoints Edwin Moses as Chair

Greywolf Therapeutics appoints renowned biotech entrepreneur Dr Edwin Moses as Chair, bringing 30+ years of life sciences leadership
August 13, 2025 02:00 ET | Source: Greywolf Therapeutics

Greywolf Therapeutics begins dosing of the first treatment to target the antigenic source of autoimmunity

Greywolf starts first trial of GRWD0715, aiming for a functional cure for autoimmunity by targeting its antigenic source.